Discontinuation of prophylaxis for Pneumocystis carinii pneumonia in HIV-1-infected patients treated with highly active antiretroviral therapy

Lancet

Volumn 353, Issue 9148, 1999, Pages 201-203

  Schneider, Margriet M E ^a   Borleffs, Jan C C ^a   Stolk, Ronald P ^a   Jaspers, Christian A J J ^a   Hoepelman, Andy I M ^a  

^a UNIVERSITY MEDICAL CENTER UTRECHT   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN;

ARTICLE; DRUG WITHDRAWAL; FOLLOW UP; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION PREVENTION; LYMPHOCYTE COUNT; MAJOR CLINICAL STUDY; PNEUMOCYSTIS PNEUMONIA; PRIMARY PREVENTION; PRIORITY JOURNAL; PROSPECTIVE STUDY; SECONDARY PREVENTION;

EID: 0033573787     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(98)07204-3     Document Type: Article

References (19)

1. Hoover DR, Saah AJ, Bacellar Het al. Clinical manifestations of AIDS in the era of pneumocystis prophylaxis. N Engl J Med. 329:1993;1922-1926.
2. Centers for Disease Control. Guidelines for prophylaxis against Pneumocystis carinii pneumonia for persons infected with human immunodeficiency virus. Morb Mortal Wkly Rep 1989; 38 S(5): 1-9.
3. USPHS/IDSA Prevention of Opportunistic Infections Working Group. 1997 USPHS/IDSA guidelines for the prevention of opportunistic infections in persons infected with the human immunodeficiency virus. MMWR Morb Mortal Wkly Rep 1997; 46: 1-46.
4. Schneider MME, Hoepelman AIH, Eeftinck Schattenkerk JKMet al. A controlled trial of aerosolized pentamidine or trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodefidiency virus infection. N Engl J Med. 327:1992;1836-1841.
5. Schneider MME, Nielsen ThL, Nelsing Set al. Efficacy and toxicity of two doses of trimethoprim-sulfamethoxazole as primary prophylaxis against Pneumocystis carinii pneumonia in patients with human immunodeficiency virus infection. J Infect Dis. 171:1995;1632-1636.
6. Palella FJJ, Delaney KM, Moorman ACet al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med. 338:1998;853-860.
7. Moore RD, Keruly JC, Chaisson RE. Decline in CMV and other opportunistic disease with combination antiretroviral therapy. Abstracts of the 5th conference on retroviruses and opportunistic infections. Chicago, 1998; 184.
8. Sepkowitz KA Effect on HAART on natural history of AIDS-related opportunistic disorders. Lancet. 351:1998;228-230.
9. Rowe PM The ups and downs of T-cell recovery in HIV-1 disease. Lancet. 350:1998;720.
10. Mouton Y, Alfandari S, Valette Met al. Impact of protease inhibitors on AIDS-defining events and hospitalizations in 10 French AIDS reference centres. AIDS. 11:1997;F101-105.
11. Roederer M Getting to the HAART of T cell dynamics. Nat Med. 4:1998;145-146.
12. Whitcup SM, Fortin E, Nussenblatt RBet al. Therapeutic effect of combination antiretroviral therapy on Cytomegalovirus retinitis. JAMA. 277:1997;1519.
13. MacDonald JC, Torriani FJ, Morse LS, Karevellas M, Reed JP, Freeman WR Lack of reactivation of cytomegalovirus (CMV) retinitis after stopping maintenance therapy in AIDS patients with sustained elevations in CD4 T cells in response to highly active antiretroviral therapy. J Infect Dis. 177:1998;1182-1187.
14. Tural C, Sirera G, Andreu Det al. Long lasting remission of cytomegalovirus retinitis without maintenance therapy in HIV-infected patients. J Infect Dis. 177:1998;1080-1083.
15. Phair J, Munoz A, Detels Ret al. The risk of Pneumocystis carinii pneumonia among men infected with human immunodeficiency virus type I. N Engl J Med. 322:1990;161-165.
16. Autran B, Carcelain G, Li TSet al. Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science. 277:1997;112-116.
17. Connors M, Kovacs S, Gea-Banacloche JCet al. HIV infection induces changes in CD+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nat Med. 3:1997;533-540.
18. Pakker NG, Notermans DW, Boer RDd, Roos MTL, Wolf Fd, Hill A Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nat Med. 4:1998;208-214.
19. Gorochov G, Neumann AU, Kereveur Aet al. Perturbation of CD4 and CD8 T cell repertoires during progression to AIDS and regulation of the CD4 repertoire during antiviral therapy. Nat Med. 4:1998;215-221.